Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN Nasal Spray Multipacks

• Approval will broaden the NARCAN
  ®
  Nasal Spray portfolio, and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication 
  

GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new multipack configurations of over-the-counter (OTC) NARCAN

Nasal Spray. This approval expands the NARCAN Nasal Spray product suite to include 6-count and 24-count multipack options, specifically designed to meet the needs of partners distributing higher volumes of naloxone. These new formats offer enhanced flexibility with the same trusted product, benefiting community programs and organizations operating large-scale, multi-site, or high-volume distribution programs.

“At Emergent, we work closely with our partners to develop solutions that help improve delivery, distribution and accessibility of NARCAN

Nasal Spray,” said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. “The introduction of NARCAN Nasal Spray multipacks marks a significant step in empowering our partners on the front lines. They can now better streamline bulk distribution, support broad preparedness efforts, and ultimately ensure that more communities and individuals have ready access to this life-saving medication in the event of an opioid overdose emergency.”  

This approval builds on Emergent's ongoing commitment to enhancing NARCAN

Nasal Spray accessibility and usability, complementing the recent FDA approval of the NARCAN Nasal Spray Carrying Case in January 2026. These efforts underscore Emergent’s comprehensive approach to equipping individuals and organizations with effective tools to combat opioid overdose deaths. The 6-count and 24-count multipacks will be made available soon to purchase for public interest customers through NARCANDirect , Emergent’s proprietary ordering and distribution platform. These multipacks are an addition to the current portfolio and will not replace existing product formats. Since the prescription launch of NARCAN Nasal Spray in 2016, more than 85 million doses have been distributed across the U.S. and Canada. Visit NARCAN.com and ReadytoRescue.com to learn more.

About NARCAN

 Nasal Spray
NARCAN  Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN  Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use as directed.

About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.